NCT03175211View on ClinicalTrials.gov

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

February 19, 2018

Study Completion Date

February 19, 2018

Conditions
Healthy
Interventions
DRUG

BI 456906

single dose

DRUG

Placebo

single dose

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY